ANICHKOV study: the effect of combined hypotensive and lipid-lowering therapy on cardiovascular complications in patients of high and very high risk.
Sergienko IV, Ansheles AA, Drapkina ОМ, Gornyakova NB, Zubareva MY, Shepel RN, Kuharchuk VV, Boytsov SA.
Sergienko IV, et al.
Ter Arkh. 2019 May 16;91(4):90-98. doi: 10.26442/00403660.2019.04.000104.
Ter Arkh. 2019.
PMID: 31094482
Clinical Trial.
When history of AH existed or AH detected at visit I, patients were randomized to scheme II (Ekvamer 5/10/10 mg/day) or III (Mertenil 10 mg/day + Ekvator 5/10 mg/day). During the observation, the treatment scheme remained unchanged, however, if the target levels of LDL-C a …
When history of AH existed or AH detected at visit I, patients were randomized to scheme II (Ekvamer 5/10/10 mg/day) or III (Mertenil 10 mg/ …